Avalo Therapeutics (AVTX) Goodwill (2017 - 2026)

Avalo Therapeutics (AVTX) has 10 years of Goodwill data on file, last reported at $10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill changed 0.0% year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.5 million (changed 0.0% YoY), and the FY2025 full-year result was $10.5 million, changed 0.02% from the prior year.
• Goodwill for Q1 2026 stood at $10.5 million, roughly flat from $10.5 million in the prior quarter.
• Across five years, Goodwill topped out at $14.4 million in Q1 2022 and bottomed at $10.5 million in Q4 2024.
• The 5-year median for Goodwill is $10.5 million (2023), against an average of $12.1 million.
• The widest annual swing landed in 2023, when Goodwill declined 27.11%; it then grew 0.02% in 2025.
• A 5-year view of Goodwill shows it stood at $14.4 million in 2022, then slipped by 27.11% to $10.5 million in 2023, then dropped by 0.02% to $10.5 million in 2024, then grew by 0.02% to $10.5 million in 2025, then changed by 0.0% to $10.5 million in 2026.
• The last three Goodwill figures came in at $10.5 million (Q1 2026), $10.5 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.

Peer Comparison